DDS is a B2B company: we do not have, and have no plans to have brands or products of our own and we do not market, directly or indirectly to consumers. The principal business model of Drug Delivery Solutions involves the licencing of our technologies and applications to interested pharmaceutical marketing companies. As an alternative to licencing, we can arrange for the supply of finished (manufactured) products, made to GMP pharmaceutical standards. 

The Company is designed to engage with potential customers by means of projects and trials designed to provide the level of testing of our products and technology applications required, from proof of principle, to stage three clinical trials and subsequent support for medical licensing. We have the flexible approach needed to accommodate the particular needs of all potential customers.

Our laboratories and staff are equipped to tackle the most difficult drug delivery formulation problems either in specific response to our customers´ needs or by patented applications of our own, which are designed to overcome a perceived problem, form the basis of a new product type, provide improved (super generic) versions of a given drug or to find an alternative solution to an existing patent.

Because our technologies are unique and novel, all such inventions are virtually free from competing patents.